Management of Parkinson's disease: Current and future pharmacotherapy

European Journal of Pharmacology

Volumn 750, Issue , 2015, Pages 74-81

  Kakkar, Ashish Kumar ^a   Dahiya, Neha ^b  

^a SAFDARJUNG HOSPITAL   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Adenosine receptor antagonist; Levodopa induced dyskinesia; Parkinson's disease; Safinamide

Indexed keywords

ADS 5102; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BOTULINUM TOXIN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DIPRAGLURANT; DM 1992; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PRAMIPEXOLE; PRELADENANT; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; ST 1535; TOLCAPONE; TOZADENANT; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIPADENANT; XP 21279; ADENOSINE A2 RECEPTOR ANTAGONIST; ALANINE; BENZYLAMINE DERIVATIVE;

ADD ON THERAPY; ADJUVANT THERAPY; BACKACHE; CLINICAL FEATURE; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EATING DISORDER; EVIDENCE BASED MEDICINE; HALLUCINATION; HEADACHE; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; INSOMNIA; LIVER TOXICITY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG THERAPY; PROCEDURES;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ALANINE; ANIMALS; BENZYLAMINES; DRUG THERAPY; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84922711837     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.01.030     Document Type: Review

References (76)

1. Adamas Pharmaceuticals Presents, 2013. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia. In: Proceedings of the World Parkinson's Congress. Available from: 〈http://www.prnewswire.com/news-releases/adamas-pharmaceuticals-presents-positive-clinical-data-for-ads-5102-a-treatment-for-levodopa-induced-dyskinesia-at-the-world-parkinsons-congress-226143931.html〉 (accessed 20.02.14.).
2. Addex Reports Positive, 2012. Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID). Available from: 〈http://www.addextherapeutics.com/investors/press-releases/news-details/?tx-ttnews[tt-news]%20=198&cHash=f988c9505eb3a270be64f5669486042b〉. (accessed 02.02.14.).
3. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 1989 366 375
4. A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López Del Val, L. Vela, and J.C. Martínez Castrillo Dopaminergic agonists in Parkinson's disease Neurologia 29 2014 230 241
5. A. Antonini, G. Abbruzzese, P. Barone, U. Bonuccelli, L. Lopiano, M. Onofrj, M. Zappia, and A. Quattrone COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features Neuropsychiatr. Dis. Treat. 4 2008 1 9
6. A. Antonini, F. Mancini, M. Canesi, R. Zangaglia, I.U. Isaias, L. Manfredi, C. Pacchetti, M. Zibetti, F. Natuzzi, L. Lopiano, G. Nappi, and G. Pezzoli Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease Neurodegener. Dis. 5 2008 244 246
7. S. Aoyama, H. Kase, and E. Borrelli Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist J. Neurosci. 20 2000 5848 5852
8. C.J. Barnum, N. Bhide, D. Lindenbach, M.A. Surrena, A.A. Goldenberg, S. Tignor, A. Klioueva, H. Walters, and C. Bishop Effects of noradrenergic denervation on l-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats Pharmacol. Biochem. Behav. 100 2012 607 615
9. Biotie Presents Tozadenant, 2013. Biotie Presents Tozadenant Phase 2b Data. In: Proceedings of the AAN Annual Meeting. Available from: 〈http://www.marketwired.com/press-release/biotie-presents-tozadenant-phase-2b-data-at-aan-annual-meeting-1770441.htm〉 (accessed 23.03.14.).
10. R. Borgohain, J. Szasz, P. Stanzione, C. Meshram, M. Bhatt, D. Chirilineau, F. Stocchi, V. Lucini, R. Giuliani, E. Forrest, P. Rice, R. Anand, and Study 016 Investigators Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations Mov. Disord.: Off. J. Mov. Disord. Soc. 29 2014 229 237
11. D.R. Brocks Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective J. Pharm. Pharm. Sci. 2 1999 39 46
12. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bédard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416
13. K.R. Chaudhuri, D.G. Healy, and A.H. Schapira Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol. 5 2006 235 245
14. P.J. Conn, G. Battaglia, M.J. Marino, and F. Nicoletti Metabotropic glutamate receptors in the basal ganglia motor circuit Nat. Rev. Neurosci. 6 2005 787 798
15. R. Constantinescu Update on the use of pramipexole in the treatment of Parkinson's disease Neuropsychiatr. Dis. Treat. 4 2008 337 352
16. Depomed Reports Top Line Data, 2012. Depomed Reports Top Line Data for Phase 2 Study in Parkinson's Disease. Available from: 〈http://www.prnewswire.com/news-releases/depomed-reports-top-line-data-for-phase-2-study-in-parkinsons-disease-177718871.html〉 (accessed 20.02.14.).
17. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, and C.M. Tanner Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 2007 384 386
18. J. Drouin-Ouellet, and R.A. Barker Stem cell therapies for Parkinson's disease: are trials just around the corner? Regen. Med. 9 2014 553 555
19. R. Dungo, and E.D. Deeks Istradefylline: first global approval Drugs 73 2013 875 882
20. K. Eggert, C. Schrader, M. Hahn, M. Stamelou, A. Rüssmann, R. Dengler, W. Oertel, and P. Odin Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications Clin. Neuropharmacol. 31 2008 151 166
21. S. Factor, M.H. Mark, R. Watts, L. Struck, A. Mori, R. Ballerini, N.M. Sussman, and On behalf of the Istradefylline 6002-US-007 Study Group A long-term study of istradefylline in subjects with fluctuating Parkinson's disease Parkinsonism Relat. Disord. 16 2010 423 426
22. FDA Issues, 2013. FDA Issues Complete Response Letter for Rytary (Carbidopa and Levodopa) Extended-Release Capsules (IPX066) New Drug Application. Available from: 〈http://www.drugs.com/nda/rytary-130125.html〉 (accessed 23.03.14.).
23. S.H. Fox Non-dopaminergic treatments for motor control in Parkinson's disease Drugs 73 2013 1405 1415
24. M. Gasmi, E.P. Brandon, C.D. Herzog, A. Wilson, K.M. Bishop, E.K. Hofer, J.J. Cunningham, M.A. Printz, J.H. Kordower, and R.T. Bartus AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease Neurobiol. Dis. 27 2007 67 76
25. Gasparini, F., Di Paolo, T., Gomez-Mancilla, B., 2013. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy. Park. Dis. Available from: 〈http://www.hindawi.com/journals/pd/2013/196028/cta/〉 (accessed 10.02.14.).
26. C.G. Goetz Charcot and Parkinson's disease S. Factor, W. Weiner, Parkinson's Disease Diagnosis and Clinical Management 2002 Demos Medical Publishing New York 19 26
27. R.A. Hauser, M. Cantillon, E. Pourcher, F. Micheli, V. Mok, M. Onofrj, S. Huyck, and K. Wolski Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial Lancet Neurol. 10 2011 221 229
28. R.A. Hauser, A. Hsu, S. Kell, A.J. Espay, K. Sethi, M. Stacy, W. Ondo, M. O'Connell, and S. Gupta Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial Lancet Neurol. 12 2013 346 356
29. R.A. Hauser, C.W. Olanow, K.D. Kieburtz, E. Pourcher, A. Docu-Axelerad, M. Lew, O. Kozyolkin, A. Neale, C. Resburg, U. Meya, C. Kenney, and S. Bandak Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial Lancet Neurol. 13 2014 767 776
30. R.A. Hauser, and M.A. Schwarzschild Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience Drugs Aging 22 2005 471 482
31. R.A. Hauser, L.M. Shulman, J.M. Trugman, J.W. Roberts, A. Mori, R. Ballerini, N.M. Sussman, and Istradefylline 6002-US-013 Study Group Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations Mov. Disord.: Off. J. Mov. Disord. Soc. 23 2008 2177 2185
32. B. Henry, S.H. Fox, D. Peggs, A.R. Crossman, and J.M. Brotchie The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinson's disease Mov. Disord.: Off. J. Mov. Disord. Soc. 14 1999 744 753
33. R.A. Hodgson, P.J. Bedard, G.B. Varty, T.M. Kazdoba, T. Di Paolo, M.E. Grzelak, A.J. Pond, A. Hadjtahar, N. Belanger, L. Gregoire, A. Dare, B.R. Neustadt, A.W. Stamford, and J.C. Hunter Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders Exp. Neurol. 225 2010 384 390
34. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, S. Fredduzzi, M.E. Cohen-Williams, G.A. Higgins, F. Impagnatiello, E. Nicolussi, L.E. Parra, C. Foster, Y. Zhai, B.R. Neustadt, A.W. Stamford, E.M. Parker, A. Reggiani, and J.C. Hunter Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 330 2009 294 303
35. H. Honig, A. Antonini, P. Martinez-Martin, I. Forgacs, G.C. Faye, T. Fox, K. Fox, F. Mancini, M. Canesi, P. Odin, and K.R. Chaudhuri Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life Mov. Disord.: Off. J. Mov. Disord. Soc. 24 2009 1468 1474
36. G. Hubsher, M. Haider, and M.S. Okun Amantadine: the journey from fighting flu to treating Parkinson's disease Neurology 78 2012 1096 1099
37. M.M. Iravani, and P. Jenner Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation J. Neural Transm. 118 2011 1661 1690
38. F.J. Jiménez-Jiménez, H. Alonso-Navarro, E. García-Martín, and J.A.G. Agúndez Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease Front. Cell. Neurosci. 8 2014 369
39. K.A. Johnson, P.J. Conn, and C.M. Niswender Glutamate receptors as therapeutic targets for Parkinson's disease CNS Neurol. Disord. Drug Targets 8 2009 475 491
40. J.H. Kordower, M.E. Emborg, J. Bloch, S.Y. Ma, Y. Chu, L. Leventhal, J. McBride, E.Y. Chen, S. Palfi, B.Z. Roitberg, W.D. Brown, J.E. Holden, R. Pyzalski, M.D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Déglon, and P. Aebischer Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science 290 2000 767 773
41. S.L. Kowal, T.M. Dall, R. Chakrabarti, M.V. Storm, and A. Jain The current and projected economic burden of Parkinson's disease in the United States Mov. Disord. 28 2013 311 318
42. P.A. Lewitt, R.A. Hauser, M. Lu, A.P. Nicholas, W. Weiner, N. Coppard, M. Leinonen, and J.-M. Savola Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) Neurology 79 2012 163 169
43. P.A. LeWitt, F.J. Huff, R.A. Hauser, D. Chen, D. Lissin, K. Zomorodi, and K.C. Cundy Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease Mov. Disord.: Off. J. Mov. Disord. Soc. 29 2014 75 82
44. P.A. LeWitt, A.R. Rezai, M.A. Leehey, S.G. Ojemann, A.W. Flaherty, E.N. Eskandar, S.K. Kostyk, K. Thomas, A. Sarkar, M.S. Siddiqui, S.B. Tatter, J.M. Schwalb, K.L. Poston, J.M. Henderson, R.M. Kurlan, I.H. Richard, L. Van Meter, C.V. Sapan, M.J. During, M.G. Kaplitt, and A. Feigin AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial Lancet Neurol. 10 2011 309 319
45. N. Magdalinou, A.J. Lees, and H. Zetterberg Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions J. Neurol. Neurosurg. Psychiatry 85 2014 1065 1075
46. C Marras, and CM Tanner Epidemiology of Parkinson's disease RL Watts, WC Koller, Movement Disorders, Neurologic Principles and Practice 2nd ed. 2004 McGraw Hill New York 177 196
47. Y. Mizuno, and T. Kondo Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease Mov. Disord. 28 2013 1138 1141
48. R.P. Munhoz, A. Cerasa, and M.S. Okun Surgical treatment of dyskinesia in Parkinson's disease Front. Neurol. 5 2014 65
49. S.-I. Muramatsu, K.-I. Fujimoto, K. Ikeguchi, N. Shizuma, K. Kawasaki, F. Ono, Y. Shen, L. Wang, H. Mizukami, A. Kume, M. Matsumura, I. Nagatsu, F. Urano, H. Ichinose, T. Nagatsu, K. Terao, I. Nakano, and K. Ozawa Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes Hum. Gene Ther. 13 2002 345 354
50. Newron and Zambon file, 2013. Newron and Zambon file for EU approval of Parkinson's drug safinamide. Available from: 〈http://www.thepharmaletter.com/article/newron-and-zambon-file-for-eu-approval-of-parkinson-s-drug-safinamide〉 (accessed 24.02.14.).
51. ® treatment for advanced Parkinson's disease: a review of efficacy and safety Parkinsonism Relat. Disord. 18 2012 916 929
52. W.H. Oertel, A. Berardelli, B.R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J.J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, and C. Trenkwalder Late (complicated) Parkinson's disease N.E. Gilhus, M.P. Barnes, M. Brainin, European Handbook of Neurological Management 2nd ed 2010 Wiley-Blackwell Oxford, UK 237 267
53. C.W. Olanow, M.B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology 72 2009 S1 136
54. M. Onofrj, L. Bonanni, and A. Thomas An expert opinion on safinamide in Parkinson's disease Expert Opin. Investig. Drugs 17 2008 1115 1125
55. P Pahwa, A Ellenbogen, J Jankovic, R Hauser, and S Fahn Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naIve early Parkinson's disease (APEX-PD trial) Mov. Disord. 26 Suppl 2 2011 S137
56. D. Panikar, and A. Kishore Deep brain stimulation for Parkinson's disease Neurol. India 51 2003 167 175
57. R.F. Pfeiffer, Z.K. Wszolek, and M. Ebadi Parkinson's Disease Second edition 2012 CRC Press FL, USA
58. Piclozotan (SUN N4057), Piclozotan (SUN N4057) for the Treatment of Levodopa-induced Dyskinesia and Increased OFF Time, n.d. Available from: 〈http://www.asubio.com/team/TeamAsubio-Update.html〉 (accessed 05.02.14.).
59. A. Pinna, S. Pontis, F. Borsini, and M. Morelli Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease Synapse 61 2007 606 614
60. E. Pourcher, H.H. Fernandez, M. Stacy, A. Mori, R. Ballerini, and P. Chaikin Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study Parkinsonism Relat. Disord. 18 2012 178 184
61. J. Reis, D. John, A. Heimeroth, H.-H. Mueller, W.H. Oertel, T. Arndt, and F. Rosenow Modulation of human motor cortex excitability by single doses of amantadine Neuropsychopharmacology 31 2006 2758 2766
62. Safinamide Phase III MOTION and SETTLE study results, 2013. In: Proceedings of the American Academy of Neurology (AAN) Annual Meeting. Available from: 〈http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=401196〉 (accessed 18.02.14.).
63. J.M. Savitt, V.L. Dawson, and T.M. Dawson Diagnosis and treatment of Parkinson disease: molecules to medicine J. Clin. Investig. 116 2006 1744 1754
64. A.H.V. Schapira Present and future drug treatment for Parkinson's disease J. Neurol. Neurosurg. Psychiatry 76 2005 1472 1478
65. K. Seppi, D. Weintraub, M. Coelho, S. Perez-Lloret, S.H. Fox, R. Katzenschlager, E.-M. Hametner, W. Poewe, O. Rascol, C.G. Goetz, and C. Sampaio The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease Mov. Disord.: Off. J. Mov. Disord. Soc. 26 Suppl 3 2011 S42 S80
66. Y. Shen, S.I. Muramatsu, K. Ikeguchi, K.I. Fujimoto, D.S. Fan, M. Ogawa, H. Mizukami, M. Urabe, A. Kume, I. Nagatsu, F. Urano, T. Suzuki, H. Ichinose, T. Nagatsu, J. Monahan, I. Nakano, and K. Ozawa Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease Hum. Gene Ther. 11 2000 1509 1519
67. B.C. Shook, and P.F. Jackson Adenosine A2A receptor antagonists and Parkinson's disease ACS Chem. Neurosci. 2 2011 555 567
68. J.C. Stoof, J. Booij, B. Drukarch, and E.C. Wolters The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way Eur. J. Pharmacol. 213 1992 439 443
69. M. Sun, G.-R. Zhang, L. Kong, C. Holmes, X. Wang, W. Zhang, D.S. Goldstein, and A.I. Geller Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector Hum. Gene Ther. 14 2003 415 424
70. Tadena N., 2013. Merck Discontinues Studies on Preladenant Drug. Available from: 〈http://online.wsj.com/article/BT-CO-20130523-715231.html〉 (accessed 15.02.14.).
71. Y. Tani, A. Ogata, M. Koyama, and T. Inoue Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats Eur. J. Pharmacol. 649 2010 218 223
72. K.C. Teo, and S.-L. Ho Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease Transl. Neurodegener. 2 2013 19
73. UK Medicines Information: Mavoglurant, 2013. Available from: 〈
74. WHO, 2014. Neurological disorders: public health challenges. Available from: 〈http://www.who.int/mental-health/neurology/neurodiso/en/〉 (accessed 23.03.14.).
75. L. Yu, H.-Y. Shen, J.E. Coelho, I.M. Araújo, Q.-Y. Huang, Y.-J. Day, N. Rebola, P.M. Canas, E.K. Rapp, J. Ferrara, D. Taylor, C.E. Müller, J. Linden, R.A. Cunha, and J.-F. Chen Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms Ann. Neurol. 63 2008 338 346
76. T.A. Zesiewicz, K.L. Sullivan, I. Arnulf, K.R. Chaudhuri, J.C. Morgan, G.S. Gronseth, J. Miyasaki, D.J. Iverson, W.J. Weiner, and Quality Standards Subcommittee of the American Academy of Neurology Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 74 2010 924 931